Status:
TERMINATED
RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-70 years
Brief Summary
RESTORE is an observational, open-label, multi-center, prospective, study enrolling Raptiva® (efalizumab) treated patients with moderate to severe chronic plaque psoriasis. The overall duration of the...
Eligibility Criteria
Inclusion
- Male or female ≥ 18 years old.
- Have a clinical diagnosis of moderate to severe chronic plaque psoriasis and be a candidate for treatment with Raptiva®.
- Are being treated or are initiating treatment with Raptiva® at time of study enrolment in accordance with the Canadian Product Monograph indication and recommendations.
- Be able to provide written informed consent.
- Agreement to participate in the study, and to disclose any medical events to the Investigator.
- The subject must be willing and able to comply with the protocol requirements for the duration of the study.
Exclusion
- Any contra-indication to Raptiva® according to the Canadian Product Monograph.
- Any simultaneous participation in another clinical evaluation trial for psoriasis
Key Trial Info
Start Date :
May 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
294 Patients enrolled
Trial Details
Trial ID
NCT00402818
Start Date
May 1 2006
End Date
July 1 2009
Last Update
August 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Information - Canada
Mississauga, Ontario, Canada